OmniAb Past Earnings Performance

Past criteria checks 0/6

OmniAb's earnings have been declining at an average annual rate of -30.8%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 6.2% per year.

Key information

-30.8%

Earnings growth rate

-31.0%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate6.2%
Return on equity-21.6%
Net Margin-308.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?

Sep 14
Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?

Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?

Jul 15
Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?

The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12
The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade

Mar 26
Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade

Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)

Feb 28
Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)

OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price

Jan 15
OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price

Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares

Nov 11
Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares

Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts

Aug 13
Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts

OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

May 14
OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

Revenue & Expenses Breakdown

How OmniAb makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:OABI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2420-633553
30 Jun 2422-623752
31 Mar 2421-633853
31 Dec 2334-513852
30 Sep 2365-303753
30 Jun 2366-273750
31 Mar 2366-223347
31 Dec 2259-222944
30 Sep 2239-322540
30 Jun 2238-281941
31 Mar 2238-251939
31 Dec 2135-271937
30 Sep 2133-241636
31 Dec 2023-181025
31 Dec 1918-14913

Quality Earnings: OABI is currently unprofitable.

Growing Profit Margin: OABI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OABI is unprofitable, and losses have increased over the past 5 years at a rate of 30.8% per year.

Accelerating Growth: Unable to compare OABI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OABI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).


Return on Equity

High ROE: OABI has a negative Return on Equity (-21.6%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies